O
GYRE icon

OrbiMed’s Gyre Therapeutics GYRE Stock Holding History

OrbiMed’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-230,587
Closed -$1.58M – 151
2021
Q4 		$1.58M Sell
230,587
-130,960
-36% -$2.24M 0.02% 152
2021
Q3 		$11.1M Buy
361,547
+79,067
+28% +$2.6M 0.12% 121
2021
Q2 		$9.17M Hold
282,480
– – 0.09% 130
2021
Q1 		$10.7M Buy
+282,480
New +$12.9M 0.1% 122

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

OrbiMed's GYRE Position: Q1 2022 in Review

OrbiMed sold out of Gyre Therapeutics (GYRE) in Q1 2022, closing a stake of 230,587 shares — an estimated $1.58M sold.

OrbiMed first reported a position in GYRE in Q1 2021 and held it in 4 quarters. The position peaked at $11.1M in Q3 2021. 43 funds tracked by Wall St. Rank hold GYRE as of Q1 2022.

  • OrbiMed reported no remaining Gyre Therapeutics position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 230,587 Gyre Therapeutics shares in Q1 2022, an estimated $1.58M.
  • OrbiMed first reported a position in Gyre Therapeutics in Q1 2021 and held it in 4 quarters.
  • OrbiMed's Gyre Therapeutics position peaked at $11.1M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.